An overflow and generally enthusiastic crowd turned out to hear U.S. Rep. Kelly Morrison field questions about a myriad of ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

U.S. House Rep. Jeff Hurd (R-Grand Junction) announced Thursday that Colorado’s 3rd Congressional District will be participating in the 2025 Congressional Art Competition.

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has reported its financial results for the year ending December ...

Most of us agree that those of us who work hard ought to make a decent living. We should be able to put food on the table, ...

CTIM-76 first patient dosed in January 2025Cash and cash equivalents of $94.4 million as of December 31, 2024Company expects its cash and cash ...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 ...

Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...